Business
Arrowhead Pharmaceuticals Receives Positive CHMP Opinion Recommending Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) in Europe
PASADENA, Calif., April 24, 2026--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (EMA CHMP) has adopted a positive opinion, recommending the approval of REDEMPLO® (plozasiran), a small interfering RNA (siRNA) medicine, as an adjunct to diet to reduce triglyceride levels in adult patients with familial chylomicronemia syndrome (FCS). FCS remains widely underdiagnosed and affects an estimated 1 to 1
About this update from Arrowhead Pharmaceuticals, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1609,"height":335,"url":"https://media.zenfs.com/en/business-wire.com/dadb282ae416a2fbcbba0f71ecf9c7c1"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/bRUlOeyYcvZ0X32qHf06yw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTIwMA--/https://media.zenfs.com/en/business-wire.com/dadb282ae416a2fbcbba0f71ecf9c7c1","width":960,"height":200},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/eqHU7WP6JxyfAkYVwaC2Fg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD01MDA-/https://media.zenfs.com/en/business-wire.com/dadb282ae416a2fbcbba0f71ecf9c7c1","width":1200,"height":250}},"lazy":false},{"type":"text","content":"– If confirmed by the European Commission, REDEMPLO would be the first and only siRNA medicine authorized in the EU for both genetically confirmed and clinically diagnosed adult patients with FCS","length":195,"tagName":"p","attribs":{}},{"type":"text","content":"– People living with FCS have extremely high triglyceride levels and a substantially higher risk of acute pancreatitis and related long-term complications, often resulting in a reduced quality of life","length":200,"tagName":"p","attribs":{}},{"type":"text","content":"– The CHMP opinion is based on positive results from the Phase 3 PALISADE study where REDEMPLO reduced triglycerides by a median of 80% from baseline and significantly fewer cases of acute pancreatitis were seen in patients using REDEMPLO compared with those using placebo","length":272,"tagName":"p","attribs":{}},{"type":"text","content":"PASADENA, Calif., April 24, 2026--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (EMA CHMP) has adopted a positive opinion, recommending the approval of REDEMPLO® (plozasiran), a small interfering RNA (siRNA) medicine, as an adjunct to diet to reduce triglyceride levels in adult patients with familial chylomicronemia syndrome (FCS). FCS remains widely underdiagnosed and affects an estimated 1 to 13 people per million globally. This rare disease is characterized by triglyceride levels that can be orders of magnitude higher than normal, leading to a substantially higher risk of developing acute, recurrent, and potentially fatal pancreatitis.","lengt...